Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

Plesner, Torben; Arkenau, Hendrik-Tobias; Gay, Francesca; Minnema, Monique C.; Boccadoro, Mario; Moreau, Philippe; Cavenagh, Jamie; Perrot, Aurore; Laubach, Jacob P.; Krejcik, Jakub; Ahmadi, Tahamtan; de Boer, Carla; Chen, Diana; Chiu, Christopher; Schecter, Jordan M.; Richardson, Paul G.

doi:https://doi.org/10.1111/bjh.15879

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

DSpace/Manakin Repository

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

Plesner, Torben; Arkenau, Hendrik-Tobias; Gay, Francesca; Minnema, Monique C.; Boccadoro, Mario; Moreau, Philippe; Cavenagh, Jamie; Perrot, Aurore; Laubach, Jacob P.; Krejcik, Jakub; Ahmadi, Tahamtan; de Boer, Carla; Chen, Diana; Chiu, Christopher; Schecter, Jordan M.; Richardson, Paul G.

(2019) British Journal of Haematology, volume 186, issue 3, pp. E35 - E39

(Letter)

Download/Full Text

An Open Access version of this item is not available due to the copyright policy of the publisher.

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: daratumumab, monoclonal antibody, multiple myeloma, relapsed/refractory multiple myeloma, plasma cell disorders, Hematology

DOI: https://doi.org/10.1111/bjh.15879

ISSN: 0007-1048

Publisher: Wiley-Blackwell

(Peer reviewed)